Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - votrient
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpb565284a99d14ce765da70a99bc090d0
identifier: http://ema.europa.eu/identifier
/EU/1/10/628/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Votrient 200 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-b565284a99d14ce765da70a99bc090d0
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/10/628/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - votrient
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Votrient is a type of medicine called a protein kinase inhibitor. It works by preventing the activity of proteins that are involved in the growth and spread of cancer cells.
Votrient is used in adults to treat:
Do not take Votrient
Warnings and precautions Talk to your doctor before taking Votrient:
High blood pressure and Votrient Votrient can raise your blood pressure. Your blood pressure will be checked before you take Votrient and while you are taking it. If you have high blood pressure you will be treated with medicines to reduce it.
If you are going to have an operation Your doctor will stop Votrient at least 7 days before your operation as it may affect wound healing. Your treatment will be restarted when the wound has adequately healed.
Conditions you need to look out for Votrient can make some conditions worse or cause serious side effects. You must look out for certain symptoms while you are taking Votrient to reduce the risk of any problems. See section 4. Children and adolescents Votrient is not recommended for people aged under 18. It is not yet known how well it works in this age group. Moreover it should not be used in children younger than 2 years of age because of safety concerns.
Other medicines and Votrient Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes herbal medicines and other medicines you ve bought without a prescription.
Some medicines may affect how Votrient works or make it more likely that you ll have side effects. Votrient can also affect how some other medicines work. These include:
Votrient with food and drink Don t take Votrient with food, as it affects the way the medicine is absorbed. Take it at least two hours after a meal or one hour before a meal (see section 3). Do not drink grapefruit juice while you are being treated with Votrient as this may increase the chance of side effects.
Pregnancy, breast-feeding and fertility Votrient is not recommended if you are pregnant. The effect of Votrient during pregnancy is not known.
Don t breast-feed while taking Votrient. It is not known whether the ingredients in Votrient pass into breast milk. Talk to your doctor about this.
Male patients (including those who have had vasectomies) who have partners who are either pregnant or who could become pregnant (including those who use other methods of contraception) should use condoms during sexual intercourse while taking Votrient and for at least 2 weeks after the last dose.
Fertility may be affected by treatment with Votrient. Talk to your doctor about this.
Driving and using machines Votrient can have side effects that may affect your ability to drive or use machines.
Votrient contains sodium This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially sodium-free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much to take The usual dose is 800 mg taken once a day. The dose can be taken as 2 tablets of 400 mg or as 4 tablets of 200 mg. The dose of 800 mg once a day is the maximum dose per day. Your doctor may need to reduce your dose if you get side effects.
When to take Don t take Votrient with food. Take it at least two hours after a meal, or one hour before a meal. For example, you could take it two hours after breakfast or one hour before lunch. Take Votrient at about the same time each day.
Swallow the tablets whole with water, one after the other. Do not break or crush the tablets as this affects the way the medicine is absorbed and may increase the chance of side effects.
If you take more Votrient than you should If you take too many tablets, contact a doctor or pharmacist for advice. If possible show them the pack, or this leaflet.
If you forget to take Votrient Do not take a double dose to make up for a forgotten dose. Just take your next dose at the usual time.
Don t stop Votrient without advice Take Votrient for as long as your doctor recommends. Don t stop unless your doctor advises you to.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible serious side effects
Swelling of the brain (reversible posterior leukoencephalopathy syndrome) Votrient can, on rare occasions, cause swelling of the brain, which may be life threatening. Symptoms include:
Hypertensive crisis (sudden and severe rise in blood pressure) Votrient can on occasion cause a sudden and severe rise in blood pressure. This is known as a hypertensive crisis. Your doctor will monitor your blood pressure while you are taking Votrient. Signs and symptoms of a hypertensive crisis may include:
Heart conditions The risks of these problems may be higher for people with an existing heart problem, or who are taking other medicines. You will be checked for any heart problems while you are taking Votrient.
Cardiac dysfunction/heart failure, heart attack Votrient can affect how well your heart pumps or can increase the likelihood of having a heart attack. Signs and symptoms include:
Changes in heart rhythm (QT prolongation) Votrient can affect heart rhythm which in some people can develop into a potentially serious heart condition known as torsade de pointes. This can result in a very fast heartbeat causing a sudden loss of consciousness. Tell your doctor if you notice any unusual changes in your heart beat, such as beating too fast or too slow.
Stroke Votrient can increase your likelihood of having a stroke. Signs and symptoms of stroke may include:
Bleeding Votrient can cause severe bleeding in the digestive system (such as stomach, oesophagus, rectum or intestine), or the lungs, kidneys, mouth, vagina and brain, although this is uncommon. Symptoms include:
Perforation and fistula Votrient can cause a tear (perforation) in your stomach or intestinal wall or the development of an abnormal connection between two parts of your digestive tract (a fistula). Signs and symptoms may include:
Liver problems Votrient can cause problems with your liver which may develop into serious conditions such as liver dysfunction and liver failure, which may be fatal. Your doctor will be checking your liver enzymes while you are taking Votrient. Signs that your liver may not be working properly may include:
Blood clots Deep vein thrombosis (DVT) and pulmonary embolism Votrient may cause blood clots in your veins, especially in your legs (deep vein thrombosis or DVT), which may also travel to your lungs (pulmonary embolism). Signs and symptoms may include:
Thrombotic microangiopathy (TMA) Votrient may cause blood clots in the small blood vessels in the kidneys and brain accompanied by a decrease in red blood cells and cells involved in clotting (thrombotic microangiopathy, TMA). Signs and symptoms may include:
Infections Infections occurring while you take Votrient may possibly become serious. Symptoms of infections may include:
Lung inflammation Votrient can, on rare occasions, cause lung inflammation (interstitial lung disease, pneumonitis), which in some people can be fatal. Symptoms include shortness of breath or cough that will not go away. You will be checked for any lung problems while you are taking Votrient. Seek medical help immediately if you get any of these symptoms.
Thyroid problems Votrient can lower the amount of thyroid hormone produced in your body. This can result in weight increase and tiredness. You will be checked for thyroid hormone levels while you are taking Votrient. Tell your doctor if you notice significant weight gain or tiredness.
Blurry or impaired vision Votrient can cause separation or tear of the lining of the back part of the eye (retinal detachment or tear). This can result in blurry or impaired vision. Tell your doctor if you notice any change in your vision.
Possible side effects (including possible serious side effects under the relevant frequency category).
Very common side effects (may affect more than 1 in 10 people):
Very common side effects that may show up in your blood or urine tests:
Common side effects (may affect up to 1 in 10 people):
Common side effects that may show up in your blood or urine tests:
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date (EXP) which is stated on the bottle and the carton. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Votrient contains
What Votrient looks like and contents of the pack Votrient 200 mg film-coated tablets are capsule-shaped, pink with GS JT marked on one side. They are supplied in bottles of 30 or 90 tablets.
Votrient 400 mg film-coated tablets are capsule-shaped, white with GS UHL marked on one side. They are supplied in bottles of 30 or 60 tablets.
Not all pack sizes or tablet strengths may be available in your country.
Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland
Manufacturer Lek Pharmaceuticals d.d. Verov kova 1526 Ljubljana Slovenia
Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany
Glaxo Wellcome, S.A. Avda. Extremadura, 3 09400 Aranda De Duero, Burgos Spain
Novartis Farmac utica S.A. Gran Via de les Corts Catalanes, 08013 Barcelona Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16
Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0
Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20
Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133
Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-b565284a99d14ce765da70a99bc090d0
Resource Composition:
Generated Narrative: Composition composition-en-b565284a99d14ce765da70a99bc090d0
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/10/628/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - votrient
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpb565284a99d14ce765da70a99bc090d0
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpb565284a99d14ce765da70a99bc090d0
identifier:
http://ema.europa.eu/identifier
/EU/1/10/628/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Votrient 200 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en